Suzhou Novosense Microelectronics (02676): Jiang Chao has been elected as the employee representative director of the fourth board of directors.
NAXIN Microelectronics (02676) issued an announcement that Mr. Jiang Chaoshang was elected as the employee representative director of the fourth board of directors at the employee representative meeting of the company held on August 5, 2026. The election of Mr. Jiang does not require approval from the shareholders of the company at the shareholders' meeting. He will serve as a member of the fourth board of directors along with the directors elected at the company's third extraordinary shareholders' meeting held on August 6, 2026, and will hold the position of executive director, with a term that aligns with that of the fourth board of directors.
Suzhou Novosense Microelectronics (02676) announced that Mr. Jiang Chaoshang was elected as the employee representative director of the fourth board of directors at the company's employee representative conference held on August 5, 2026. The election of Mr. Jiang does not require approval from the company's shareholders at the shareholders' meeting. He will serve as a member of the fourth board of directors along with the directors elected at the company's third extraordinary shareholders' meeting (extraordinary shareholders' meeting) held on August 6, 2026, and will hold the position of executive director, with a term consistent with that of the fourth board of directors.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





